Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports on the adjourned Annual General Meeting of Shareholders held on August 7, 2026. The filing confirms the approval of all proposed resolutions by the shareholders of Redhill Biopharma Ltd., an Israel-based biopharmaceutical company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and shareholder resolutions rather than financial performance data.
Material Changes and Corporate Actions
- Auditor Re-appointment: Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) was re-appointed as the Company's auditors for 2026 and until the next Annual General Meeting.
- Board Elections: Mr. Rick D. Scruggs and Dr. Shmuel Cabilly were re-elected to the Board of Directors for an additional three-year term ending in 2029.
- Executive Leadership: The engagement of Dr. Dror Ben-Asher as Chairman of the Board of Directors and Chief Executive Officer was approved.
- Articles of Association: The Company amended its Articles of Association to eliminate the par value of its shares.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, specific risks, contingencies, or unusual items. It serves strictly as a record of the shareholder meeting outcomes.
Key Facts for Investor Verification
- Verify the effective date of the share par value elimination and its impact on capital structure.
- Confirm the tenure and compensation details of the newly re-appointed auditors for the 2026 fiscal year.
- Review the full scope of Dr. Dror Ben-Asher's dual role as Chairman and CEO for potential governance implications.
- Check subsequent filings for the aggregate auditor compensation for the year ended December 31, 2025, which was disclosed to shareholders but not detailed in this text.